The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Valuation Is Forecasted For The Cancer Diagnostics Market By 2030 Starting From Its 2026 Size?
The cancer diagnostics market has experienced rapid expansion over recent years. This market is projected to expand from $25.5 billion in 2025 to $28.58 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.1%. Factors contributing to its historical growth include the increasing global prevalence of cancer, greater investments in oncology research, an enlarged hospital diagnostic infrastructure, wider acceptance of imaging for cancer detection, and advancements in laboratory automation.
The cancer diagnostics market is projected to experience substantial expansion over the coming years. By 2030, this market is predicted to reach a valuation of $44.69 billion, demonstrating a compound annual growth rate (CAGR) of 11.8%. This anticipated growth during the forecast timeframe is attributable to a surge in demand for tailored cancer treatments, increased uptake of next-generation sequencing diagnostic methods, broadened population-level cancer screening initiatives, escalating investments in AI-powered oncology diagnostics, and ongoing advancements in tests for detecting multiple cancers. Key trends anticipated in the upcoming period encompass a greater embrace of molecular and companion diagnostics, the increasing incorporation of artificial intelligence in identifying cancer, an expanding utilization of biomarker-driven testing, the proliferation of high-throughput diagnostic platforms, and a heightened emphasis on screening for cancer at early stages.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2570&type=smp
Which Market Drivers Are Supporting The Expansion Of The Cancer Diagnostics Market?
The growth of the cancer diagnostics market is anticipated to be driven by increasing healthcare spending in the future. Healthcare expenditure encompasses all financial resources allocated by governments, businesses, and individuals towards health services, such as medical treatments, hospital care, medications, and public health programs. This growing demand for healthcare funds stems from the increasing occurrence of chronic illnesses, which necessitate expensive and extended treatment plans. Increased healthcare investment boosts cancer diagnostics by facilitating the integration of advanced screening tools and broadening access to early detection facilities. It also sharpens diagnostic precision through enhanced funding for modern equipment and specialized laboratories, allowing for prompt intervention and improved patient results. For example, in May 2024, the Office for National Statistics, a UK government department, reported that total healthcare expenditure rose by 5.6% in nominal terms in 2023, representing a 0.9% growth from 2022. Consequently, the expansion of the cancer diagnostics market is being propelled by the surge in healthcare expenditure.
Which Segment Categories Define The Cancer Diagnostics Market?
The cancer diagnostics market covered in this report is segmented –
1) By Products: Companion Diagnostics, Molecular Diagnostics
2) By Method: Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging
3) By Application: Cervical Cancer, Breast Cancer, Liver Cancer, Blood Cancer, Kidney Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma, Other Applications
4) By End-User: Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Other End Users
Subsegments:
1) By Companion Diagnostics: Biomarker-Based Companion Diagnostics, Genetic Testing-Based Companion Diagnostics, Immunohistochemistry-Based Companion Diagnostics, PCR-Based Companion Diagnostics, Other Companion Diagnostics,
2) By Molecular Diagnostics: Polymerase Chain Reaction (PCR) Diagnostics, Next-Generation Sequencing (NGS) Diagnostics, In Situ Hybridization Diagnostics, Microarray-Based Diagnostics, DNA Or RNA Extraction Kits, Other Molecular Diagnostics
What Major Market Trends Are Driving Changes In The Cancer Diagnostics Market?
Leading companies within the cancer diagnostic device market are prioritizing the creation of technology utilizing artificial intelligence (AI), such as QAi Prostate, to secure a competitive advantage. QAi Prostate functions as a cancer diagnostic device for prostate cancer diagnosis. For instance, in March 2023, Qritive, a Singapore-based company focused on developing AI-powered diagnostic tools for pathologists, introduced QAi Prostate. QAi Prostate is an advanced artificial intelligence (AI)-powered prostate cancer diagnosis tool. QAi Prostate leverages machine learning algorithms to accurately pinpoint and categorize malignant and benign areas in prostate tissue samples. This tool is engineered to aid pathologists in detecting prostate cancer and distinguishing between malignant and benign areas within prostate tissue samples.
Who Are The Top Companies Competing In The Cancer Diagnostics Market?
Major companies operating in the cancer diagnostics market are Abbott Laboratories, Becton Dickinson and Company, Hologic, GE Healthcare Ltd., Thermo Fisher Scientific, Siemens Healthcare GmbH, Biogenex Laboratories, Veracyte, PathAI, Bio-Rad Laboratories, BioChain, DiagnoCure, Illumina, Myriad Genetics, CompanionDx, Epic Sciences, Genomic Health, Affymetrix, Agilent Technologies, Adaptive Biotechnologies, Biocartis, Biocept, Cancer Genetics Inc., Caris Life Sciences, Cepheid, Epigenomics AG, Exact Sciences, Foundation Medicine, GenMark Diagnostics, Guardant Health, HalioDX, Invitae Corporation, NanoString Technologies, Natera, NeoGenomics, Oncura Inc., PerkinElmer, Personal Genome Diagnostics, Qiagen, Roche Diagnostics
Read the full cancer diagnostics market report here:
https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report
How Is The Cancer Diagnostics Market Distributed Across Key Geographic Regions?
North America was the largest region in the cancer diagnostics market in 2025. Asia-Pacific was the second-largest region in the global cancer diagnostics market. The regions covered in the cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Cancer Diagnostics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=2570&type=smp
Browse Through More Reports Similar to the Global Cancer Diagnostics Market 2026, By The Business Research Company
Oncology Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report
Clinical Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report
Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model